H3 Biomedicine

H3 Biomedicine Presents Preclinical Data on Novel ERα antagonist at San Antonio Breast Cancer Symposium

Selective Estrogen Receptor Covalent Antagonist (SERCA) inactivates both wild-type and mutant ERα Read More

H3 Biomedicine to Present New Data on H3B-6527, an FGFR4 Inhibitor, at the 2017 International Liver Cancer Association Annual Meeting

Presentation to highlight pre-clinical data on H3’s Lead Solid Tumor Compound Read More

H3 Biomedicine Announces First Patient Dosed with H3B-6545 in Phase 1 Study in Breast Cancer

Read More

H3 Biomedicine Granted Orphan Drug Designation of H3B-8800 for Treatment of Acute Myelogenous Leukemia and Chronic Myelomonocytic Leukemia

Read More

H3 Biomedicine and University of British Columbia Scientists Report Preclinical Data Describing Immune Evasion Mechanism in Muscle-Invasive Bladder Cancer

Article published in current issue of Nature Communications details that the PPARγ/RXRα pathway constitutes a tumor-intrinsic mechanism underlying immune evasion… Read More

H3 Biomedicine’s Preclinical Data Highlighting Novel Discovery Research around Splicing Modulators Published in Current Issue of Nature Communications

Read More

H3 Biomedicine Appoints Lihua Yu, Ph.D., to Chief Data Sciences Officer

Read More

H3 Biomedicine Extends Collaboration with Foundation Medicine to Develop Precision Therapies for Cancer

Read More

H3 Biomedicine Presents New Data from its RNA Splicing Platform at AACR

Includes the Characterization of Splicing Modulator Mechanism of Action and Demonstration of Pre-clinical Efficacy of H3B-8800 in Spliceosome Mutant Cancers,… Read More

H3 Biomedicine to Present Data on Emerging Pipeline Compounds

Data Updates on FGFR4 Inhibitor for Hepatocellular Carcinoma (HCC) and Novel Selective Estrogen Receptor Covalent Receptor (SERCA) Identified for Breast… Read More